Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

3010 - Final analysis of patient-reported-outcomes (PRO) and early intervention to toxicities as tools for improving compliance of patients with metastatic colorectal cancer (mCRC) treated with aflibercept + FOLFIRI (A-FOLFIRI) under real-world-conditions in Germany

Date

08 Oct 2016

Session

Poster Display

Presenters

Rainer Lipp

Citation

Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370

Authors

R. Lipp, M. Feuerbach, F. Freigang, P. Brecht

Author affiliations

  • Rwe Research, GermanOncology GmbH, 20457 - Hamburg/DE
More

Resources

Abstract 3010

Background

Therapies with A-FOLFIRI in mCRC showed in up to a quarter of patients toxicity-related or patient-triggered discontinuations. The rationale of this study was to describe effects on treatment duration and compliance by using continious recordings of PRO and defined toxicities under the real-world-conditions of oncological practices in Germany.

Methods

Patients with mCRC were assigned and analysed in 2 cohorts: cohort 1 with standardized requests for PRO (visual analog scale and QoL) and defined toxicities (diarrhea, hypertension, fatigue, infections) and cohort 2 without these requests. The patients were treated with a standard protocol of A-FOLFIRI in several therapy lines. The assignments for one of the cohorts were based on decisions of the oncologists.

Results

Data of n = 112 patients (44% women, 56% men, mean age 71,8 years) were sampled between Jan 2014 and Feb 2016 in 18 oncological practices. In cohort 1 n = 37 patients got requests for QoL before start of every cycle and a diary for recording performance by VAS and specific toxicities. In cohort 2 n = 75 patients were guided based on standard oncologist's practice. QoL and VAS data were available in 81% and 67% and showed over all lines a mean of maximal uptake of 9,3 and 7,3 points, respectively. Over all lines A-FOLFIRI was administered for 8,3 cycles (16,8 weeks) in cohort 1 and 7,3 cycles (13,7 weeks) in cohort 2. An appearance of toxicities (≥ 3° CTC 4.0) was transmitted to the oncologist in a mean of 3,2 days. The rates of early discontinuations due to toxicities or patient's wishes could be declined by 5,2% (13,1% cohort 1 vs. 18,3% cohort 2) and dose reductions by 3,5% (17,3% cohort 1 vs. 20,8% cohort 2).

Conclusions

In this cohort study requests for PRO and early intervention to toxicities showed in patients with mCRC under A-FOLFIRI a prolongation of the therapy and a reduction of discontinuations. Recording of PRO and early intervention to toxicities may be a good opportunity to improve patient's compliance and should be tested in a randomised trial with innovative telematic systems.

Clinical trial identification

not applicable

Legal entity responsible for the study

GermanOncology GmbH (Managing Director: Dr. Rainer Lipp)

Funding

GermanOncology GmbH

Disclosure

R. Lipp: Financial support of research project by Sanofi. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings